PERRY DRUG HAS MORE AUTO PARTS UNITS THAN DRUG STORES
PERRY DRUG HAS MORE AUTO PARTS UNITS THAN DRUG STORES following Perry's acquisition of 46 Corvair discount auto parts stores. The acquisition of the Columbus, Ohio-based auto chain with annual sales of approximately $22 mil. will raise the number of auto stores operated by Perry to 150, compared with 143 drug stores, according to an Oct. 10 release announcing a definitive agreement between the two firms. The acquisition is the fifth by Perry in as many months, and the third purchase of an auto parts chain since June. Automotive sales are expected to account for as much as 22% of total sales for Perry in fiscal 1984, which ends Oct. 31, a company spokesman told "The Pink Sheet." Last year, net automotive sales were $40.1 mil., representing 14% of Perry's total net sales of $200.2 mil. Rx volume remains a key segment in Perry's sales mix, however. In 1983, Rx sales increased 35% to $56.4 mil., representing approximately 20% of total sales. Rx and automotive sales combined are expected to account for between 40% to 43% of total sales in fiscal 1984. According to a company spokesman, Perry's goal is for combined automotive and Rx sales to reach 50% of the chain's total sales within the next few years.
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.
HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.
Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.